Guardant Health (GH) is down roughly 3% in Tuesday trading (April 28, 2026) after the company disclosed a leadership change: Chief Medical Officer Craig Eagle, M.D. has resigned, with his departure effective May 8, 2026. Management transitions at the top of medical, clinical, and regulatory functions can pressure sentiment for diagnostics and life-science names, especially when investors are focused on commercialization execution and near-term milestones.

The resignation was disclosed April 27, 2026, placing the news directly in front of today’s session and giving the market limited time to digest succession expectations. The timing also intersects with an approaching catalyst: Guardant is scheduled to report first-quarter 2026 financial results on May 7, 2026 after the close, a window when traders often reduce risk and volatility can increase on incremental headlines.

Near term, investors will look for clarity on interim clinical leadership, any changes to clinical-development cadence, and whether the company signals continuity around regulatory and reimbursement priorities. With earnings coming up on May 7, 2026, focus will likely shift quickly to revenue growth, margin trajectory, and management commentary on demand trends across its testing portfolio.